Author

V. A. Miller

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1 Approach:statistical model· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

A. G. Waks· 1 shared A. R. Lau· 1 shared A. Regev· 1 shared A. Safa· 1 shared D. E. Root· 1 shared E. P. Winer· 1 shared F. Federica Piccioni· 1 shared J. Chung· 1 shared

Activity by Year

2019-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. G. Waks

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pharmacology & ToxicologybioRxivJul 25, 2020

Pharmacological prevention of neonatal opioid withdrawal in a pregnant guinea pig model.

A. Safa, A. R. Lau, S. Aten…·J. Oberdick

This study shows that 6β-naltrexol prevents neonatal opioid withdrawal in guinea pigs by blocking opioid dependence with high potency.

DOI 10.3389/fphar.2020.613328

𝕏 PostBluesky

Cancer BiologybioRxivOct 7, 2019

Acquired FGFR and FGF alterations confer resistance to estrogen receptor (ER) targeted therapy in ER+ metastatic breast cancer

P. Mao, O. Cohen, K. J. Kowalski…·N. Wagle

This study identifies FGFR and FGF pathway alterations as acquired resistance mechanisms to ER-targeted therapy in ER+ metastatic breast cancer and suggests targeted inhibitors as potential treatments.

DOI 10.1158/1078-0432.ccr-19-3958

humanwhole-exome sequencing

𝕏 PostBluesky